{"id":"https://openalex.org/W4237018690","doi":"https://doi.org/10.1158/1538-7445.sabcs18-ct078","title":"Abstract CT078: Cyfi: Results from a Phase Ib expansion cohort of anti-hepatocyte growth factor and cytarabine in relapsed and refractory AML","display_name":"Abstract CT078: Cyfi: Results from a Phase Ib expansion cohort of anti-hepatocyte growth factor and cytarabine in relapsed and refractory AML","publication_year":2019,"publication_date":"2019-07-01","ids":{"openalex":"https://openalex.org/W4237018690","doi":"https://doi.org/10.1158/1538-7445.sabcs18-ct078"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.sabcs18-ct078","doi":"https://doi.org/10.1158/1538-7445.sabcs18-ct078","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.sabcs18-ct078","pdf_url":null,"source":{"id":"https://openalex.org/S59378366","display_name":"Clinical Trials","issn_l":"1740-7745","issn":["1740-7745","1740-7753"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","jufo-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Trials","raw_type":"proceedings-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5062376578","display_name":"Victoria E. H. Wang","orcid":"https://orcid.org/0000-0001-9052-3531","observed_orcids":["https://orcid.org/0000-0001-9052-3531"]},"institutions":[{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Victoria E. Wang","raw_affiliation_strings":["UCSF, San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCSF, San Francisco, CA","institution_ids":["https://openalex.org/I180670191"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5068715900","display_name":"Charalambos Babis Andreadis","orcid":"https://orcid.org/0000-0003-4681-6227","observed_orcids":["https://orcid.org/0000-0003-4681-6227"]},"institutions":[{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Charalambos Andreadis","raw_affiliation_strings":["UCSF, San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCSF, San Francisco, CA","institution_ids":["https://openalex.org/I180670191"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I180670191"],"apc_list":{"value":4150,"currency":"USD","value_usd":4150},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":"CT078","last_page":"CT078"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11559","display_name":"Retinoids in leukemia and cellular processes","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cytarabine","display_name":"cytarabine","score":0.9369999766349792},{"id":"https://openalex.org/keywords/autocrine-signaling","display_name":"autocrine signaling","score":0.5260000228881836},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.4950000047683716},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.8460000157356262},{"id":"https://openalex.org/keywords/febrile-neutropenia","display_name":"febrile neutropenia","score":0.8169999718666077},{"id":"https://openalex.org/keywords/inflammatory-markers","display_name":"inflammatory markers","score":0.628000020980835},{"id":"https://openalex.org/keywords/tnf-alpha","display_name":"TNF-\u03b1","score":0.7480000257492065},{"id":"https://openalex.org/keywords/interferon-gamma","display_name":"interferon-gamma","score":0.9150000214576721},{"id":"https://openalex.org/keywords/single-cell-rna-sequencing","display_name":"single-cell RNA sequencing","score":0.7829999923706055},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.7120000123977661},{"id":"https://openalex.org/keywords/complete-response","display_name":"complete response","score":0.6359999775886536}],"concepts":[{"id":"https://openalex.org/C2778041864","wikidata":"https://www.wikidata.org/wiki/Q180983","display_name":"Cytarabine","level":3,"score":0.6741504073143005},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.6652857065200806},{"id":"https://openalex.org/C2776996007","wikidata":"https://www.wikidata.org/wiki/Q2399112","display_name":"Hepatocyte growth factor","level":3,"score":0.5727664232254028},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.5240036249160767},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4830096960067749},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.48005211353302},{"id":"https://openalex.org/C44280652","wikidata":"https://www.wikidata.org/wiki/Q104837","display_name":"Phase (matter)","level":2,"score":0.43676748871803284},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4362873136997223},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.39130234718322754},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.20976388454437256},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.1691707968711853},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.1224115788936615},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.0657041072845459},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0},{"id":"https://openalex.org/C178790620","wikidata":"https://www.wikidata.org/wiki/Q11351","display_name":"Organic chemistry","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.sabcs18-ct078","doi":"https://doi.org/10.1158/1538-7445.sabcs18-ct078","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.sabcs18-ct078","pdf_url":null,"source":{"id":"https://openalex.org/S59378366","display_name":"Clinical Trials","issn_l":"1740-7745","issn":["1740-7745","1740-7753"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","jufo-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Trials","raw_type":"proceedings-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2892053009","https://openalex.org/W3185291790","https://openalex.org/W2887965682","https://openalex.org/W7108502605","https://openalex.org/W4242439176","https://openalex.org/W4405047454","https://openalex.org/W2098290171","https://openalex.org/W3010820032","https://openalex.org/W2410184824","https://openalex.org/W1625508716"],"abstract_inverted_index":{"Objective:":[0],"Patients":[1],"with":[2,61,77,106,276,290],"AML":[3,80,342],"who":[4,82,244],"are":[5,83,198],"refractory":[6,84,298,341],"to":[7,52,66,85,183,250,260,278,313],"induction":[8],"therapy":[9],"or":[10,87,130],"relapse":[11],"within":[12,90],"1":[13,91,225,242],"year":[14,92],"have":[15,32,88],"poor":[16],"outcomes.":[17],"Elevated":[18],"serum":[19],"hepatocyte":[20],"growth":[21,334],"factor":[22,335],"(HGF)":[23],"level":[24],"is":[25,286,302],"an":[26,40,107,111],"adverse":[27],"prognostic":[28],"factor.":[29],"Pre-clinical":[30],"models":[31],"shown":[33],"that":[34,274],"myeloid":[35],"blasts":[36,51],"produce":[37],"HGF":[38],"in":[39,79,124,293,304,338],"autocrine":[41],"fashion":[42],"and":[43,70,116,204,220,229,241,269,284,297,336,340],"pharmacologic":[44],"blockade":[45],"of":[46,72,93,110,127,159,187,316,332,346],"the":[47,68,73,103,119,149,190,239,247,347],"HGF/c-Met":[48],"axis":[49],"sensitizes":[50],"cell":[53,177],"death.":[54],"We":[55],"initiated":[56],"a":[57,156,266,287,327],"Phase":[58,104,306,328],"Ib":[59,329],"study":[60,65,248],"dose":[62,145,158],"expansion":[63,108,150,330],"cohort":[64,109,331],"assess":[67,184],"safety":[69],"tolerability":[71],"anti-HGF":[74],"antibody":[75],"ficlatuzumab":[76,256,279,285],"cytarabine":[78,337],"patients":[81,114,193],"7+3":[86],"relapsed":[89,296,339],"induction.Methodology:":[94],"The":[95],"3":[96,98],"x":[97],"design":[99],"was":[100,122,146,153,181,224],"used":[101,147,182,312],"for":[102,133,148,350],"I":[105],"additional":[112],"13":[113],"accrued":[115,194],"treated":[117],"at":[118,155,168,280],"MTD.":[120],"Ficlatuzumab":[121],"administered":[123,154],"escalated":[125],"dosing":[126],"10,":[128],"15,":[129],"20":[131,143],"mg/Kg":[132,144],"4":[134,252],"doses":[135],"every":[136],"2":[137,160],"weeks":[138],"starting":[139],"on":[140,162,232],"day":[141,233],"1.":[142],"cohort.":[151],"Cytarabine":[152,283],"fIxed":[157],"g/m2":[161],"days":[163],"2-7.":[164],"PBMCs":[165],"were":[166,215],"collected":[167],"defined":[169],"time":[170],"points.":[171],"Differential":[172],"expression":[173],"from":[174,227,238,246,326],"multiplexed":[175],"single":[176],"RNA":[178],"sequencing":[179,264],"(scRNAseq)":[180],"biomarkers":[185,315],"predictive":[186],"response.Results:":[188],"Of":[189],"total":[191],"18":[192],"thus":[195],"far,":[196],"16":[197],"evaluable.":[199],"5":[200],"had":[201],"progressive":[202],"disease,":[203,240],"11":[205],"responded,":[206],"all":[207],"complete":[208],"responses.":[209],"Most":[210],"frequent":[211],"grade":[212,251],"3/4":[213],"TEAEs":[214],"febrile":[216],"neutropenia,":[217],"LFT":[218],"abnormalities,":[219],"electrolyte":[221],"disturbance.":[222],"There":[223],"death":[226],"sepsis":[228],"multi-organ":[230],"failure":[231],"23,":[234],"following":[235],"ANC":[236],"recovery,":[237],"patient":[243],"withdrew":[245],"due":[249],"gastrointestinal":[253],"bleed,":[254],"likely":[255],"related,":[257],"both":[258],"prior":[259],"response":[261,277],"assessment.":[262],"scRNA":[263],"identified":[265],"TNF":[267],"alpha":[268],"IFN":[270],"gamma":[271],"inflammatory":[272],"signature":[273],"correlates":[275],"count":[281],"recovery.Conclusion:":[282],"safe":[288],"combination":[289,301],"promising":[291],"efficacy":[292],"high":[294],"risk":[295],"AML.":[299],"This":[300],"warranted":[303],"further":[305],"II":[307],"studies.":[308],"scRNAseq":[309],"may":[310],"be":[311],"identify":[314],"response.Citation":[317],"Format:":[318],"Victoria":[319],"E.":[320],"Wang,":[321],"Charalambos":[322],"Andreadis.":[323],"Cyfi:":[324],"Results":[325],"anti-hepatocyte":[333],"[abstract].":[343],"In:":[344],"Proceedings":[345],"American":[348],"Association":[349],"Cancer":[351,365],"Research":[352],"Annual":[353],"Meeting":[354],"2019;":[355],"2019":[356],"Mar":[357],"29-Apr":[358],"3;":[359],"Atlanta,":[360],"GA.":[361],"Philadelphia":[362],"(PA):":[363],"AACR;":[364],"Res":[366],"2019;79(13":[367],"Suppl):Abstract":[368],"nr":[369],"CT078.":[370]},"counts_by_year":[],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2022-05-12T00:00:00"}